Phenotypes associated with this allele

• Allele Symbol: Hdac1^tm1.1Mrl
• Allele Name: targeted mutation 1.1, Merck Research Laboratory
• Allele ID: MGI:5494616
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl Hdac2^tm1.1Rdp/Hdac2^tm1.1Rdp Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:5494632
cn2	Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl Hdac2^tm1.1Rdp/Hdac2^+ Tg(Mx1-cre)1Cgn/0	involves: 129S4/SvJae * C57BL/6 * CBA	MGI:5494631
cn3	Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl Hdac2^tm1.1Rdp/Hdac2^tm1.1Rdp Tg(Mx1-cre)1Cgn/0	involves: 129S4/SvJae * C57BL/6 * CBA	MGI:5494633
cn4	Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA	MGI:5494630

Genotype
MGI:5494632

cn1

• Allelic Composition: Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl; Hdac2^tm1.1Rdp/Hdac2^tm1.1Rdp; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal mitosis ( J:197818 )

• tamoxifen-treated mouse embryonic fibroblasts exhibit a 2-fold reduction in S-phase cells and an increase in G1 phase cell compared with control cells

decreased fibroblast proliferation ( J:197818 )

• tamoxifen-treated mouse embryonic fibroblasts exhibit growth arrest compared with control cells

early cellular replicative senescence ( J:197818 )

• in tamoxifen-treated mouse embryonic fibroblasts

Genotype
MGI:5494631

cn2

• Allelic Composition: Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl; Hdac2^tm1.1Rdp/Hdac2⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

hematopoietic system

anemia ( J:197818 )

• in pIpC-treated mice

decreased bone marrow cell number ( J:197818 )

• in pIpC-treated mice

abnormal megakaryocyte morphology ( J:197818 )

• megakaryocytes from pIpC-treated mice exhibit aberrant nuclear morphology and mitotic figures and are frequently found intra-vascular or extravasating into bone marrow blood vessels and in the liver compared with control cells

decreased megakaryocyte cell number ( J:197818 )

• in the bone marrow of pIpC-treated mice without increased apoptosis

decreased erythrocyte cell number ( J:197818 )

• 2-fold in pIpC-treated mice

thrombocytopenia ( J:197818 )

• 6-fold in pIpC-treated mice

behavior/neurological

lethargy ( J:197818 )

• in pIpC-treated mice

Genotype
MGI:5494633

cn3

• Allelic Composition: Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl; Hdac2^tm1.1Rdp/Hdac2^tm1.1Rdp; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

mortality/aging

premature death ( J:197818 )

• mice are moribund 9 days after pIpC treatment

hematopoietic system

anemia ( J:197818 )

• in pIpC-treated mice

decreased bone marrow cell number ( J:197818 )

• in pIpC-treated mice

decreased megakaryocyte cell number ( J:197818 )

• 20-fold in the bone marrow of pIpC-treated mice with increased apoptosis

decreased erythrocyte cell number ( J:197818 )

• 5-fold in pIpC-treated mice

thrombocytopenia ( J:197818 )

• 16-fold in pIpC-treated mice

cellular

increased apoptosis ( J:197818 )

• apoptotic megakaryocytes in pIpC-treated mice

behavior/neurological

lethargy ( J:197818 )

• in pIpC-treated mice

cardiovascular system

internal hemorrhage ( J:197818 )

• in pIpC-treated mice

Genotype
MGI:5494630

cn4

• Allelic Composition: Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA

hematopoietic system

hematopoietic system phenotype ( J:197818 )

N • pIpC-treated mice exhibit normal liver and bone marrow

liver/biliary system

liver/biliary system phenotype ( J:197818 )

N • pIpC-treated mice exhibit normal liver and bone marrow